ClinicalTrials.gg
CompletedNCT02191228Updated Jul 16, 2014

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

A Phase 1 interventional study of Linagliptin - single dose and Linagliptin - Multiple dose in Renal Insufficiency, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-16.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Renal Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · Boehringer Ingelheim.

Enrollment
2nd of 11
51 · median 35
Started
2008
the only one that year
Phase 1
10 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Renal Insufficiency by Boehringer Ingelheim, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 10 in phase 1, and was the 7th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 11 studies in Renal Insufficiency by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Renal Insufficiency by Boehringer Ingelheim as a file.
02

Study summary

The main objective of this study was to assess the effect of normal and impaired renal function on the safety, pharmacokinetics, and pharmacodynamics of linagliptin following oral administration of 5 mg daily for 7 days (Groups 1 to 3), 5 mg daily for 10 days (Groups 6 and 7), or as a single dose (Groups 4 and 5)

03

Conditions studied

  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with normal renal function, defined as a (CrCl) of >80 mL/min on screening (Group 1) , or male or female patients with Type 2 diabetes mellitus (T2DM) and normal renal function, defined as a CrCl of >80 mL/min on screening (Group 7)
  • Male or female patients with Renal impairment (RI), determined by the value of CrCl on Screening estimated according to the Cockcroft-Gault formula. Patients were classified into groups by their CrCl values:

    • Mild RI: CrCl>50 to ≤80 mL/min (Group 2)
    • Moderate RI: CrCl>30 to ≤50 mL/min (Group 3)
    • Severe RI: CrCl≤30 mL/min (Group 4)
    • End-stage renal disease (ESRD): CrCl≤30 mL/min, requiring hemodialysis (Group 5)
    • T2DM and severe RI: CrCl≤30 mL/min (Group 6)
  • Age 18 to 80 years
  • 18 to 40 kg/m2, and minimum body mass of at least 45 kg for females
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria

Exclusion Criteria:

Participants (with or without RI) who met any of the following criteria were not included in this trial:

  • Relevant gastrointestinal tract surgery (except appendectomy, cholecystectomy, or herniotomy)
  • Diseases of the central nervous system, such as epilepsy, seizures, relevant neurological disorders, or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure \<100 or >160 mm Hg, diastolic blood pressure \<60 or >100 mm Hg, pulse rate \<50 or >100 1/min
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergies) that were deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (>24 h) within at least one month prior to study start, or planned intake of study medication within ≤10 half-lives of administration of another medication. Medications that patients with RI were currently taking for treatment of renal disease were not included under this criterium.
  • Use of medications during the trial or within 10 days prior to administration of study medication that might reasonably influence the results of the trial, based on knowledge at the time of protocol preparation. Co-medications known to inhibit or induce P-glycoprotein or were not allowed. Inhibitors of P-glycoprotein or CYP3A include protease inhibitors (such as ritonavir, lopinavir, nelfinavir); azole antimycotics, (itraconazole, ketoconazole, miconazole); macrolide antibiotics, (clarithromycin, erythromycin); amiodarone, cimetidine, diltiazem, fluvoxamine, mibefradil, nefazodone, verapamil, tacrolimus, quinidine, reserpine, and cyclosporine A. Inducers of P-gp or CYP3A include carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St. John's Wort and troglitazone. In uncertain cases, a case-by-case decision was made after consultation with the sponsor.
  • Participation in a previous trial with an drug within 2 months of study start if the previous trial was a multiple dose study, or within 1 month of study start if the previous trial was a single dose study
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking when confined to the study site on trial days
  • Alcohol abuse (more than 60 g/day in males or more than 40 g/day in females)
  • Drug abuse, in the investigator's judgment, based on review of the participant's history and urine screening for abused substances
  • Veins unsuited for intravenous puncture on either arm (e.g. veins which were difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture)
  • Blood donation (more than 100 mL within 4 weeks prior to administration of study medication or during the trial)
  • Excessive physical activities (within 48 h prior to start of the trial or during the trial)
  • Any laboratory value outside the reference range that was of clinical relevance (exceptions were in patients with RI who had abnormal renal function tests or deviations of clinical laboratory values that were related to renal impairment)
  • Inability to comply with the dietary regimen of study centre
  • Inability to understand and comply with protocol requirements, instructions and protocol-stated restrictions

For female patients

  • Pregnancy
  • Positive pregnancy test (human chorionic gonadotropin (β HCG) in urine))
  • No adequate in women of (adequate contraception was considered to be sterilisation, use of an intrauterine device, or use of oral contraception along with a barrier method)
  • Lactation period

Subjects with normal renal function (Group 1) and subjects with T2DM and normal renal function (Group 7) who met the following criterium were not included in this trial:

  • Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator

Patients with RI who met any of the following criteria were not included in this trial:

  • Moderate and severe concurrent liver function impairment (for example, due to hepatorenal syndrome)
  • Patients with significant diseases other than renal impairment were excluded. A significant disease was defined as a disease which in the opinion of the investigator put the patient at risk during participation in the study, could influence the results of the study, could influence the patient's ability to participate in the study, or was an unstable condition. Patients with diabetes (for Groups 1 to 5) or hypertension could be included in the trial if the disease was not significant according to these criteria.
  • \<8 g/dL, indicating severe anaemia of renal origin (use of erythropoietin was allowed to maintain haematocrit)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Group 1

    Linagliptin in subjects with normal renal function

    Drug: Linagliptin - Multiple dose

  • Experimental
    Group 2

    Linagliptin in patients with mild renal insufficiency (RI)

    Drug: Linagliptin - Multiple dose

  • Experimental
    Group 3

    Linagliptin in patients with moderate RI

    Drug: Linagliptin - Multiple dose

  • Experimental
    Group 4

    Linagliptin in patients with severe RI

    Drug: Linagliptin - single dose

  • Experimental
    Group 5

    Linagliptin in patients with end-stage renal disease (ESRD)

    Drug: Linagliptin - single dose

  • Experimental
    Group 6

    Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)

    Drug: Linagliptin - Multiple dose

  • Experimental
    Group 7

    Linagliptin in patients with normal renal function and T2DM

    Drug: Linagliptin - Multiple dose

Interventions

  • DrugLinagliptin - single dose
  • DrugLinagliptin - Multiple dose
06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the last dose at steady state) - multiple dose groups

    Time frame: up to 480 hours

  2. Cmax,ss (maximum concentration of the analyte in plasma at steady state) - multiple dose groups

    Time frame: up to 480 hours

  3. AUC0-24 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the first dose) - single dose groups

    Time frame: up to 24 hours

  4. Cmax (maximum concentration of the analyte in plasma) - single dose groups

    Time frame: up to 264 hours

Secondary outcomes

  1. tmax,(ss) (time from last dosing to maximum concentration of the analyte in plasma after the first dose or at steady state) - multiple dose groups

    Time frame: up to 480 hours

  2. C24,(ss) (concentration of the analyte in plasma at steady state after administration of the first or last dose at the end of the dosing interval) - multiple dose groups

    Time frame: up to 480 hours

  3. λz,(ss) (terminal rate constant in plasma after single dose/at steady state) - multiple dose groups

    Time frame: up to 480 hours

  4. t1/2,(ss) (terminal half-life of the analyte in plasma after single dose/at steady state) - multiple dose groups

    Time frame: up to 480 hours

  5. MRTpo,(ss) (mean residence time of the analyte in the body after single dose/at steady state after oral administration) - multiple dose groups

    Time frame: up to 480 hours

  6. CL/F,(ss) (apparent clearance of the analyte in the plasma after extravascular administration after single dose/at steady state) - multiple dose groups

    Time frame: up to 480 hours

  7. Vz/F,(ss) (apparent volume of distribution during the terminal phase λz after single dose/at steady state following extravascular administration) - multiple dose groups

    Time frame: up to 480 hours

  8. AUC0-∞ (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose in severely impaired or end stage renal disease (ESRD) patients)

    Time frame: up to 264 hours

  9. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point after single dose in severely impaired or ESRD patients)

    Time frame: up to 264 hours

  10. %AUCtz-∞ (percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity after single dose in severely impaired or ESRD patients)

    Time frame: up to 264 hours

  11. Assessment of Plasma protein binding

    Time frame: predose Day 1

  12. Model-derived AUCτ,ss in severely impaired or ESRD patients

    Time frame: up to 264 hours

  13. Model-derived Cmax,ss in severely impaired or ESRD patients

    Time frame: up to 264 hours

  14. Change in Dipeptidyl peptidase IV (DPP-4) activity in plasma

    Time frame: up to 480 hours

  15. Number of patients with abnormal findings in physical examination

    Time frame: up to day 32

  16. Number of patients with clinically significant changes in vital signs

    Time frame: up to day 32

  17. Number of patients with abnormal changes 12-lead ECG (electrocardiogram)

    Time frame: up to day 32

  18. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to day 32

  19. Number of patients with adverse events

    Time frame: up to 53 days

  20. Assessment of tolerability by investigator on a 4-point scale

    Time frame: up to 480 hours

  21. AUC0-24 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the first dose) - multiple dose groups

    Time frame: up to 24 hours

  22. Cmax (maximum concentration of the analyte in plasma) - multiple dose groups

    Time frame: up to 480 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008 and a primary completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2014
First posted
Jul 16, 2014
Start
Apr 2008
Primary completionActual
Feb 2010
Last update
Jul 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02191228
Responsible party
Sponsor
First posted
Jul 16, 2014
Start date
Apr 2008
Primary completion
Feb 2010
Last update
Jul 16, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion